– USA, NJ – Avalon GloboCare Corp. (OTCQB:AVCO), a leading global developer of cell-based technologies, today announced that it has appointed William B. Stilley to the Company’s board of directors. In addition, Mr. Stilley will head the board’s audit committee.
Mr. Stilley currently serves as Chief Executive Officer of Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder. Prior to joining Adial, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. At Clinical Data, Inc., Mr. Stilley worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the company’s vasodilator drug for myocardial stress imaging. Mr. Stilley also served as the COO and CFO of Adenosine Therapeutics, LLC where he ran the internal operations of the company, including research and development, and all financing activity, until the sale of its principal assets to Clinical Data, Inc. Mr. Stilley has advised both public and private companies on financing and M&A transactions, has been the interim CFO of a public company, the interim Chief Business Officer of Diffusion Pharmaceuticals, and the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps. Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He has guest lectured at the Darden School of Business on the management of life science companies and serves on the Board of Virginia BIO, the statewide biotechnology organization. He also holds patents for Stedivaze®, which is currently in Phase 3 clinical development.
David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp., “We are pleased to welcome an executive of Bill’s stature to the board of directors, in addition to his role as head of our audit committee. He brings extensive experience within the biotechnology industry having held a variety of senior corporate positions, including his current role as CEO of Adial Pharmaceuticals. He brings valuable operational, financial and strategic experience, including product licensing, partnering, financing, M&A and more. We look forward to his contributions as we expand the global sales of our exosome isolation system, advance exosome-based therapeutics through clinical development, and prepare to list on a senior U.S. exchange.”
“I am delighted to join the board of Avalon at this exciting time in the Company’s development,” stated Mr. Stilley. “Avalon is developing cutting edge cell-based therapies and technologies that hold enormous potential in the fields of in vitro diagnostics, regenerative medicine and cancer immunotherapy.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB:AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely “Avalon Cell” and “Avalon Rehab.” In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients’ growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.
For more information : http://www.avalon-globocare.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.